Find here all our blog posts tagged with: PCCP.

Abstract image of two intersecting light arcs, one medical and one technological in form, with a visible unaligned gap between them.

The Change-Control Gap Between MDR and the AI Act

Predetermined change control plans reveal the specific reconciliation gap between MDR/IVDR certification and EU AI Act obligations for adaptive medical algorithms.

A clinician reaches toward a glowing network of data nodes, half crisp and half dissolving into static, above a hospital bed.

AI Clinical Decision Support Is Scaling Past Its Evidence

FDA clearance and predetermined change control plans govern AI software lifecycle, not clinical benefit, leaving hospitals to own the evidence gap.

A surgical tray under split lighting, part crisp and part blurred, evoking a medical AI system in continuous change after approval.

Clearance Was Never the Finish Line

FDA's predetermined change control pathway shifts the real compliance burden from initial authorization to lifecycle governance of AI models after they ship.

A hand balances a scale between a stack of paper files and a shifting glowing sphere, symbolizing documentation valued against an unsettled standard.

The MedTech Compliance Asset Has a Shelf Life

MedTech buyers are pricing compliance documentation as a deal asset, but the standards that file is graded against are still being written.

A medical AI device shown updating freely on one side and sealed under multiple regulatory stamps on the other.

The Continuous-Update Trap in Medical AI Governance

FDA now lets manufacturers update AI devices without new submissions, but EU's MDR/IVDR and AI Act stack offers no equivalent, forcing a split lifecycle strategy.

Abstract image of countless glowing data strands funneling into a narrow beam of light, symbolizing regulatory oversight straining against a surge of AI-driven medical data.

The Governance Gap Behind FDA's AI Device Surge

FDA's AI-enabled device authorizations are scaling faster than lifecycle governance infrastructure, and the same gap is now stalling AI drug discovery approvals.

A consumer wearable device and a clinical ultrasound probe positioned on opposite sides of a lit boundary line representing FDA's shifting device classification.

FDA's AI Perimeter Is Widening and Narrowing at the Same Time

FDA is loosening wellness device classification while tightening AI change control mechanics, and the gap between the two is where compliance risk now sits.

A single small gear straining to drive a much larger network of interlocked gears, symbolizing regulatory capacity strain.

When the Regulator's Capacity Becomes Your Risk

FDA's shrinking resourcing and the MDUFA VI negotiations mean AI device sponsors can no longer treat PCCP approval as the end of verification.

Abstract photograph of light flowing between a human hand and a robotic diagnostic arm, symbolizing continuous oversight of AI in medicine.

FDA's Discussion Paper Moves the Goalposts on GenAI Devices

FDA's generative AI discussion paper signals a shift from one-time approval to continuous, competency-based testing that life sciences compliance teams should prepare for now.

Abstract image of a clinician's hand meeting a translucent data structure in a softly lit hospital corridor, symbolizing continuous performance evaluation.

The FDA's Open Docket Is the Real Deadline

FDA's move toward assessing generative AI devices like clinicians raises real feasibility questions, but sponsors who wait for guidance will lose the argument.

A translucent sphere with an internal crack suspended over a grid of light, symbolizing a hidden flaw inside an approved AI-enabled medical device.

FDA's Lifecycle Bet on GenAI-Enabled Devices

FDA is easing premarket friction for AI-enabled devices while shifting the real compliance burden to post-market monitoring that current guidance cannot yet catch.

A clinical monitor showing an AI-annotated lung scan beside a regulatory approval document on a desk.

The Benchmark Gap Inside FDA's AI Change Control Plans

FDA's Predetermined Change Control Plan guidance lets AI devices update without new submissions, but no validated benchmarking standard tells manufacturers where drift becomes risk.

Abstract layered forms contrasting a fixed structure with a fluid, shifting one to evoke static documentation versus adaptive systems.

MedTech Diligence Now Has to Read Change Plans, Not Just Technical Files

AI-enabled devices are adding predetermined change control plans to MDR/IVDR technical files, and buyers evaluating MedTech targets need to diligence both.

Three colored channels of a river diverging and reconverging under a misty dawn sky, symbolizing parallel regulatory pressures on a single timeline.

MDUFA VI Is a Capacity Signal, Not the Whole Story

The MDUFA VI negotiation matters for AI device review capacity, but sponsors treating it as the sole variable are missing parallel forces already shaping their timelines.

An illuminated paper hovers above a dim archive of closed files, symbolizing a single publication mistaken for finished regulatory guidance.

A Journal Article Is Not a Regulatory Safe Harbor

A Nature Medicine audit framework for AI mental health tools is being framed as a de facto FDA standard, but no published mechanism makes that so.

Aerial view of a river forking into two channels, symbolizing diverging US and EU regulatory paths for AI medical devices

The PCCP Illusion: Why US Speed Doesn't Buy EU Clearance

FDA's finalized change control pathway lets AI devices update without new submissions, but the EU AI Act demands continuous oversight that PCCPs were not built to satisfy.

A bridge cable splitting into two diverging strands over water, symbolizing regulatory paths that have not yet converged.

The PCCP's Global Convergence Is a Hypothesis, Not Yet a Standard

IMDRF has laid out principles for regulators to adopt predetermined change control plans, but FDA and the EU's MDR/IVDR regime remain far from aligned.

Gloved hands adjusting a translucent medical device model under clinical blue lighting.

The PCCP Is the Real Decision, Not the Generative AI Docket

FDA's Predetermined Change Control Plan guidance, not the open generative AI docket, is the mechanism sponsors must decide on now for AI-enabled devices.

Abstract image of a mechanical gate within a glowing network of pathways, some open and some sealed, symbolizing controlled change management.

The Clearance Isn't the Risk. The Change Control Plan Is.

As high-risk AI medical devices scale, the decisive diligence question shifts from FDA clearance status to what a manufacturer's change control plan permits it to alter unsupervised.

A luminous bridge connecting two distinct rock formations, symbolizing a unified regulatory pathway between separate compliance regimes.

The PCCP Window Before the AI Act Deadline Closes

IMDRF's new PCCP principles and the EU AI Act's delayed medtech deadline create a narrow window to build one change control architecture instead of two.

A river delta splitting into two divergent channels, symbolizing diverging regulatory paths for AI-enabled medical devices.

The Quality System Nobody Rebuilt Yet

FDA's living PCCP model for AI-enabled devices demands continuous evidence trails that most design control systems were never built to produce.

A wearable health device shown split between a clinical, regulated half and a consumer wellness half, illustrating the FDA's shifting classification line.

FDA Just Moved the Wellness Line. That Is a Liability Decision, Not a Compliance Break

FDA's broadened wellness classification for AI-enabled wearables forces life sciences leaders to choose their liability posture, not just their regulatory burden.